Dipeptidyl Aminopeptidase-Like Protein 6 (DPPX) Antibody, IgG by CBA-IFA With Reflex to Titer, Serum
Aids in diagnosis of limbic encephalitis. May be used to monitor treatment response in individuals who initially test positive for DPPX antibodies. The presence of DPPX antibodies may be associated with hyperexcitability, pleocytosis, and frequent diarrhea. DPPX encephalitis may be paraneoplastic; hematologic malignancies are reported in a subset of patients.
Semi-Quantitative Cell-Based Indirect Fluorescent Antibody
New York DOH Approval Status
Serum separator tube.
Separate serum from cells within 2 hours of collection. Transfer 1 mL serum to an ARUP standard transport tube. (Min: 0.2 mL)
CSF or plasma. Contaminated, hemolyzed, or severely lipemic specimens.
After separation from cells: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: 30 days (avoid repeated freeze/thaw cycles)
Effective November 15, 2021
Less than 1:10
DPPX antibody is found in a subset of patients with autoimmune encephalitis, and is often associated with prodromal gastrointestinal symptoms and unintentional weight loss. It may occur with or without associated tumor. Decreasing antibody levels may be associated with therapeutic response. A negative test result does not rule out a diagnosis of autoimmune neurologic disease. Results should be interpreted in correlation with the patient's clinical history and other laboratory findings.
This indirect fluorescent antibody assay utilizes DPPX transfected cells for the detection and semiquantification of the DPPX IgG antibody.
Laboratory Developed Test (LDT)
If DPPX antibody IgG is positive, then DPPX antibody IgG titer will be added. Additional charges apply.
86255; if reflexed, add 86256
|Component Test Code*||Component Chart Name||LOINC|
|3004361||DPPX Ab IgG CBA-IFA Screen, Serum||94676-4|
- Autoimmune dysautonomia
- Movement disorder
- Progressive encephalomyelitis